SG/PUT/ASTRAZENECA/12000/0.1/21.06.24 | Delayed Deutsche Boerse AG 09:00:31 21/05/2024 pm IST | ||
| 0.15 EUR | -50.00% |
|
| Current month | -28.57% | ||
| 1 month | -75.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 0.15 | -50.00% |
| 20/24/20 | 0.3 | +3.45% |
| 17/24/17 | 0.29 | +3.57% |
| 16/24/16 | 0.28 | 0.00% |
| 15/24/15 | 0.28 | +16.67% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 09:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SV48V4 |
| ISIN | DE000SV48V44 |
| Date issued | 11/05/2023 |
| Strike | 12,000 p |
| Maturity | 21/06/2024 (31 Days) |
| Parity | 10 : 1 |
| Emission price | 1.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.1 € |
|---|---|
| Lowest since issue | 0.15 € |
| Spread | 0.04 € |
| Spread % | 22.22% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Warrants
- Warrant
